Neuhofer J, Fritsch P
Acta Derm Venereol. 1984;64(2):171-4.
Eight patients with lichen sclerosus and 8 patients with localized scleroderma were treated with etretinate (Tigason) at doses of 0.5 mg/kg body weight for between 3 and 12 months: 2 of 3 patients with juvenile type lichen sclerosus cleared, whereas the lesions of 5 patients with balanitis xerotica obliterans, kraurosis vulvae and extragenital lichen sclerosus were unchanged or even progredient. 2 of the patients with localized scleroderma cleared with slight atrophy. The lesions of 5 others failed to resolve but progression was halted under continued therapy; after drug withdrawal, the lesions resumed progression in 2 patients. We conclude that only moderate therapeutic effects can be achieved with etretinate in both lichen sclerosus and localized scleroderma.
8例硬化性苔藓患者和8例局限性硬皮病患者接受了依曲替酯（银屑灵）治疗，剂量为0.5mg/kg体重，疗程3至12个月：3例青少年型硬化性苔藓患者中有2例症状消退，而5例闭塞性干燥性龟头炎、外阴干枯症和生殖器外硬化性苔藓患者的皮损未改变甚至进展。2例局限性硬皮病患者症状消退，伴有轻度萎缩。另外5例患者的皮损未消退，但在持续治疗下病情停止进展；停药后，2例患者的皮损恢复进展。我们得出结论，依曲替酯在硬化性苔藓和局限性硬皮病中只能取得中等程度的治疗效果。
